Parabilis Medicines presents updated Phase 1/2 data for zolucatetide
PBLS•Parabilis Medicines reported a 72.2% objective response rate at 32 weeks among desmoid tumor patients receiving a starting dose of at least 450 mg of zolucatetide.
1. Updated trial data
Parabilis Medicines presented updated Phase 1/2 data for zolucatetide, reporting a 72.2% objective response rate at 32 weeks for patients with desmoid tumors who received a starting dose of at least 450 mg. The company described the safety and tolerability profile as favorable.
